Evidence map›Paper›PMID 40150877›Full record

ArticleCPT: pharmacometrics & systems pharmacology2025

Precision Medicine in Oncology: Imatinib Dosing in the Obese Cancer Population Using Virtual Clinical Trials.

Khairulanwar Burhanuddin, Afzal Mohammed, Nurul Afiqah Burhanuddin, Raj K S Badhan

Abstract read
In one paragraph

Article in CPT: pharmacometrics & systems pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Khairulanwar BurhanuddinNational Pharmaceutical Regulatory Agency, Ministry of Health Malaysia, Petaling Jaya, Malaysia.ORCID https://orcid.org/0000-0001-9242-7914
Afzal MohammedSchool of Pharmacy, College of Health and Life Science, Aston University, Birmingham, UK.
Nurul Afiqah BurhanuddinDepartment of Mathematical Science, Science and Technology, Universiti Kebangsaan Malaysia, Bangi, Selangor, Malaysia.ORCID https://orcid.org/0000-0002-2990-1414
Raj K S BadhanSchool of Pharmacy, College of Health and Life Science, Aston University, Birmingham, UK.ORCID https://orcid.org/0000-0002-0904-9324

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study investigates the impact of obesity on imatinib pharmacokinetics in cancer patients by utilizing physiologically based pharmacokinetic modeling (PBPK) and virtual clinical trial approaches and evaluates the effectiveness of therapeutic drug monitoring (TDM)-guided dose adjustment to recover the imatinib trough concentration (C

Indexed as

Antineoplastic AgentsImatinib MesylateNeoplasmsObesityPrecision MedicineAdultAgedBody Mass IndexBody Surface AreaClinical Trials as TopicComputer SimulationCytochrome P-450 CYP3ADose-Response Relationship, DrugDrug MonitoringFemaleHumansAntineoplastic AgentsCytochrome P-450 CYP3AImatinib Mesylatecancer obesityimatinibPBPKpharmacokineticsTDM

Identifiers

PMID40150877
PMCPMC12167919

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.